JAMA Network Open
February 3, 2025
Li Ren, Ting Zhang, Bingyu Zou et al.
13 citations
Esketamine has been found to reduce the incidence of postpartum depression (PPD) in randomized clinical trials. However, current evidence from randomized clinical trials does not reflect esketamine's efficacy in clinical settings. To assess the clinical efficacy of intraoperative esketamine administration for preventing PPD among women who underwent cesarean delivery. This randomized clinical...
The International Journal of Neuropsychopharmacology
February 1, 2025
*Laura Musazzi, J. Mingardi, P. Misztak et al.
Abstract Background The stress response is a physiological event finely orchestrated by the brain and aimed at restoring the homeostasis lost in case of environmental changes perceived as dangerous for survival. Most subjects successfully activate an adaptive stress response however, when the exposure to stressful stimuli is prolonged over time or overwhelming, some individuals may fail in...
The International Journal of Neuropsychopharmacology
February 1, 2025
Kengo Yonezawa, Hideaki Tani, Shuhei Shibukawa et al.
Abstract Background Whereas ketamine has displayed robust antidepressant effects in treatment-resistant depression (TRD) (Han et al., 2016), only 30-40% of patients with TRD respond to ketamine therapy (Wilkinson et al., 2018; Sakurai et al., 2020). Several postmortem studies have shown decreased myelination in patients with depression (Hamidi, Drevets and Price, 2004; Altshuler et al., 2010),...
Cannabis and Cannabinoid Research
February 1, 2025
Margy Y. Chen, Emily B Kramer, Laurel P Gibson et al.
Objective: Cannabis has been touted for a host of pharmacological and therapeutic effects and users commonly report reduced symptoms of physical and mental health conditions, including anxiety, depression, and chronic pain. While there is existing empirical evidence supporting these effects of cannabis use, little is known about the extent to which these effects result from pharmacological...
The International Journal of Neuropsychopharmacology
February 1, 2025
Hui-Ju Wu, *Mu-Hong Chen, Wei-Chen Lin
Abstract Background The role of neurofilament light chain (NFL) in treatment-resistant depression (TRD) is unclear. Whether baseline NFL concentrations are associated with the antidepressant effects of low- dose ketamine infusion has not been determined. Methods The NFL concentrations of 71 patients with TRD and 17 healthy controls were assessed. Patients with TRD were randomly administered a...
The International Journal of Neuropsychopharmacology
February 1, 2025
Leonard Lerer, Kathleen Spear, Jeet Varia et al.
Abstract Background Psilocybin research in depression has been generated using chemically synthesized psilocybin (PSI). Psychedelic mushrooms produce additional tryptamines that may enhance the neuroplastic effect of psilocybin. In a rodent depression model, an extract of a psychedelic mushroom (PME) had a stronger and more prolonged effect than PSI on behavior[1]. Aims and Objectives To...
The International Journal of Neuropsychopharmacology
February 1, 2025
Rebecca Harding, Natalie Ertl, Rayyan Zafar
Abstract Major Depressive Disorder (MDD) is a highly prevalent mental health condition characterized by symptoms including anhedonia, which is defined as diminished pleasure, and impulsivity, which has been linked to increased substance abuse, self-harm and suicidal tendencies. Both anhedonia and impulsivity have been contributed to alterations in reward system function, with the striatum being...
Psychopharmacology
February 1, 2025
Jiabao Dai, Yanfeng Lu, Zhiqing Zou et al.
11 citations
Previous studies have reported conflicting findings regarding the efficacy of esketamine in managing postoperative depression. While the positive effects of subanesthetic doses esketamine have been observed in treatment-resistant depression, the response to this medication in patients experiencing depression following surgery has not been consistent. Building upon the known impact of anesthesia...
Journal of Affective Disorders
February 1, 2025
Farzaneh Ramezani, Peyman Mardani, Fatemeh Nemati et al.
4 citations
Over the last two decades, ketamine has gained significant interest in psychiatry as a potential treatment for major depressive disorder (MDD), especially in individuals who are resistant to traditional therapies or are at a high risk of suicide. Task-based functional magnetic resonance imaging (fMRI) studies can provide insight into how ketamine alters brain function and contributes to its...
European Neuropsychopharmacology
February 1, 2025
Danica E. Johnson, Nelson B Rodrigues, Sydney Weisz et al.
Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatments. Although ketamine shows promise as a rapid-acting antidepressant for treatment-resistant depression (TRD), its effectiveness in patients with comorbid PTSD remains underexplored. Therefore, we conducted a retrospective analysis of 134 patients...